Protective Effect of Ginsenoside Rg5 on Hypoxia/Reoxygenation- Induced H9c2 Cardiomyocytes by Correcting Free Fatty Acids β- oxidation
Abstract Clinically, the in-hospital mortality rate of cardiogenic shock (CS) is approximately 50%. In CS, metabolic pathways in the body undergo “embryonal transformation,” in which metabolic processes transform free fatty acids (FFAs) to glucose. Shenfu injection (SFI) treatment has exhibited a positive effect on cardiogenic shock, and ginsenoside Rg5 (G-Rg5) is the anticardiogenic shock component of SFI. In this study, we aimed to investigate the myocardial protective effect and mechanism of G-Rg5 in myocardial energy metabolism, especially from the perspective of FFA β-oxidation, one of the most crucial lipid metabolism pathways. Cardiomyocytes were exposed to hypoxia-reoxygenation (H/R) and treated with G-Rg5. MTT analysis was used to determine the viability of H9c2 cardiomyocytes under different interventions with G-Rg5. The levels of lactate dehydrogenase (LDH) and FFA were detected using ELISA, and adenosine triphosphate (ATP) was determined using high-performance liquid chromatography (HPLC). Furthermore, the expression of NR4A1 was determined by RT-qPCR, and the levels of AMPKα, p-AMPKα, and GPX4 were detected by western blotting to explore the underlying mechanism. We observed that G-Rg5-protected H9c2 cardiomyocytes exhibited better FFA β-oxidation regulation, thereby producing an increased abundance of ATP. G-Rg5 may correct FFA β-oxidation by regulating the levels of NR4A1, AMPKα, p-AMPKα, and GPX4. Therefore, G-Rg5 is a promising drug for CS treatment..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 24. Juni Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Li. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2812492/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA039435482 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA039435482 | ||
| 003 | DE-627 | ||
| 005 | 20230625130259.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230503s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2812492/v1 |2 doi | |
| 035 | |a (DE-627)XRA039435482 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2812492/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Li. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protective Effect of Ginsenoside Rg5 on Hypoxia/Reoxygenation- Induced H9c2 Cardiomyocytes by Correcting Free Fatty Acids β- oxidation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Clinically, the in-hospital mortality rate of cardiogenic shock (CS) is approximately 50%. In CS, metabolic pathways in the body undergo “embryonal transformation,” in which metabolic processes transform free fatty acids (FFAs) to glucose. Shenfu injection (SFI) treatment has exhibited a positive effect on cardiogenic shock, and ginsenoside Rg5 (G-Rg5) is the anticardiogenic shock component of SFI. In this study, we aimed to investigate the myocardial protective effect and mechanism of G-Rg5 in myocardial energy metabolism, especially from the perspective of FFA β-oxidation, one of the most crucial lipid metabolism pathways. Cardiomyocytes were exposed to hypoxia-reoxygenation (H/R) and treated with G-Rg5. MTT analysis was used to determine the viability of H9c2 cardiomyocytes under different interventions with G-Rg5. The levels of lactate dehydrogenase (LDH) and FFA were detected using ELISA, and adenosine triphosphate (ATP) was determined using high-performance liquid chromatography (HPLC). Furthermore, the expression of NR4A1 was determined by RT-qPCR, and the levels of AMPKα, p-AMPKα, and GPX4 were detected by western blotting to explore the underlying mechanism. We observed that G-Rg5-protected H9c2 cardiomyocytes exhibited better FFA β-oxidation regulation, thereby producing an increased abundance of ATP. G-Rg5 may correct FFA β-oxidation by regulating the levels of NR4A1, AMPKα, p-AMPKα, and GPX4. Therefore, G-Rg5 is a promising drug for CS treatment. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Fang, Wenjie |4 aut | |
| 700 | 1 | |a Zhang, Wentong |4 aut | |
| 700 | 1 | |a Tu, Yu |4 aut | |
| 700 | 1 | |a Shang, Guangbin |4 aut | |
| 700 | 1 | |a Zhang, Qiyun |4 aut | |
| 700 | 1 | |a Nie, Peng |4 aut | |
| 700 | 1 | |a Yan, Xiaojun |4 aut | |
| 700 | 1 | |a Liu, Hongning |4 aut | |
| 700 | 1 | |a Xu, Guoliang |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 24. Juni |
| 773 | 1 | 8 | |g year:2023 |g day:24 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2812492/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 24 |c 06 | ||